Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Indolent lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    114 result(s) found for: Indolent lymphoma. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2012-002602-52 Sponsor Protocol Number: BAY80-6946/16349 Start Date*: 2012-10-19
    Sponsor Name:Bayer AG
    Full Title: Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas
    Medical condition: Patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas or patients with follicular lymphoma relapsed after or refractory to standard therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    20.0 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    20.0 100000004851 10029608 Non-Hodgkin's lymphomas unspecified histology aggressive HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed) SE (Completed) PL (Completed) AT (Completed) PT (Completed) HU (Completed) DK (Prematurely Ended) IE (Completed) GR (Completed) LU (Completed)
    Trial results: View results
    EudraCT Number: 2011-004908-37 Sponsor Protocol Number: IRIS Start Date*: 2011-10-21
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Phase II study on activity and tolerability of intralesional rituximab in relapsed or refractory patients affected by indolentCD-20 positive lymphoma of conjuntiva; evaluation of activity of adding...
    Medical condition: indolent CD-20 positive lymphoma of conjunctiva
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015504-25 Sponsor Protocol Number: GAO4753g Start Date*: 2010-06-04
    Sponsor Name:GENENTECH, Inc
    Full Title: An Open Label, Multicenter, randomized, phase III study to investigate the efficacy and safety of Bendamustine compared with Bendamustine + RO5072759 (GA101) in patients with Rituximab-refractory, ...
    Medical condition: CD20+, indolent NHL
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) AT (Completed) DE (Completed) FR (Completed) IT (Completed) GB (Completed) ES (Completed) SE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019248-37 Sponsor Protocol Number: IILINFL09 Start Date*: 2010-12-30
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular Non-Hodgkin’s Lymphoma
    Medical condition: Patients with advanced untreated Indolent non Follicular non-Hodgkin Lymphomas
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016725-34 Sponsor Protocol Number: C18083/2048 Start Date*: 2010-05-21
    Sponsor Name:Cephalon, Inc.
    Full Title: An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL)
    Medical condition: Non-Hodgkin’s Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004830-81 Sponsor Protocol Number: FIL_BArT Start Date*: 2015-12-24
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A multicenter study to evaluate the anti-viral activity of an interferon-free treatment with ledipasvir/sofosbuvir (G1 and G4) and sofosbuvir/velpatasvir (G2 and G3) for patients with hepatitis C v...
    Medical condition: Patients with hepatitis C virus-associated indolent B-cell lymphomas
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    20.1 10021881 - Infections and infestations 10065051 Acute hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001635-34 Sponsor Protocol Number: 3129K7-2001-WW Start Date*: 2009-05-21
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research & Development
    Full Title: A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects With Indolent Non-Hodgkin’s Lymphoma (NHL) That is Refractory to or has Relapsed After Rituximab and Chemotherapy or Radioimmunotherapy
    Medical condition: Indolent Non-Hodgkin's Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065856 Non-Hodgkin's lymphoma unspecified histology indolent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Prematurely Ended) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003093-27 Sponsor Protocol Number: PCI-32765FLR3001 Start Date*: 2013-12-18
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination with Either Bendamustine and Rituximab (BR) or Rituxim...
    Medical condition: Indolent Non-Hodgkin Lymphoma (iNHL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-024132-41 Sponsor Protocol Number: BO21223 Start Date*: 2011-06-14
    Sponsor Name: F. Hoffmann-La Roche Ltd.
    Full Title: A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) PLUS CHEMOTHERAPY C...
    Medical condition: INDOLENT NON-HODGKIN'S LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) SE (Completed) DE (Completed) HU (Completed) FR (Completed) ES (Completed) IT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-003460-19 Sponsor Protocol Number: BO21003 Start Date*: 2009-05-12
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease.
    Medical condition: Patients with relapsed CD20+ indolent NHL will be enrolled (Relapsed defined as; relapsed indolent lymphoma with documented history of response [CR, CRu, or PR) of≥6 months in duration from the com...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) SE (Completed) NL (Completed) DK (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003408-29 Sponsor Protocol Number: 5F9003 Start Date*: 2019-11-04
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
    Medical condition: Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029624 Non-Hodgkin's lymphoma unspecified histology indolent stage III PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029601 Non-Hodgkin's lymphoma refractory PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029623 Non-Hodgkin's lymphoma unspecified histology indolent stage II PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029622 Non-Hodgkin's lymphoma unspecified histology indolent stage I PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-003657-24 Sponsor Protocol Number: BRIL06 Start Date*: 2006-09-06
    Sponsor Name:GIMURELL
    Full Title: A PHASE II MULTICENTER NON-RANDOMIZED STUDY TO ASSESS SAFETY, TOXICITY AND CLINICAL ACTIVITY OF THE ASSOCIATION OF BORTEZOMID VELCADE WITH RITUXIMAB IN RELAPSED/REFRACTORY INDOLENT NON FOLLICULAR...
    Medical condition: relapsed non follicular non-Hodgkin s Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10029621 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005225-81 Sponsor Protocol Number: VALYM Start Date*: 2021-04-28
    Sponsor Name:LYSARC
    Full Title: A PHASE II OPEN-LABEL STUDY EVALUATING VALEMETOSTAT TOSYLATE AS A SINGLE AGENT IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMA
    Medical condition: RELAPSE/REFRACTORY B-CELL LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001088-38 Sponsor Protocol Number: BAY80-6946/17833 Start Date*: 2015-12-09
    Sponsor Name:Bayer AG
    Full Title: A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in p...
    Medical condition: Patients with relapsed indolent non-Hodgkin's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) DE (Prematurely Ended) BE (Completed) CZ (Completed) DK (Prematurely Ended) ES (Prematurely Ended) GB (Completed) FR (Completed) PL (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) HU (Completed) SK (Prematurely Ended) GR (Completed) BG (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002989-33 Sponsor Protocol Number: COLPRIT-0000-BAS-0041-I Start Date*: 2023-06-29
    Sponsor Name:Klinikum rechts der Isar der Technischen Universität München
    Full Title: CHEMOKINE RECEPTOR CXCR4-DIRECTED THERANOSTICS OF ADVANCED LYMPHOPROLIFERATIVE CANCERS BY RADIOPEPTIDE-BASED IMAGING AND THERAPY: THE COLPRIT PHASE I/II STUDY
    Medical condition: Indication: Non-Hodgkin lymphomas (NHL) Advanced lymphoproliferative cancers: aggressive B- and T- cell Non-Hodgkin lymphomas (NHL), including heavily pretreated transformed indolent lymphoma (tNHL...
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023335-41 Sponsor Protocol Number: 16011 Start Date*: 2011-11-23
    Sponsor Name:Abbott
    Full Title: A Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed Indolent Lymphoma
    Medical condition: Relapsed Indolent Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001912-13 Sponsor Protocol Number: KTE-C19-105 Start Date*: 2018-04-24
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) (ZUMA-5)
    Medical condition: Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (r/r) iNHL.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002733-39 Sponsor Protocol Number: ML18324 Start Date*: 2005-04-06
    Sponsor Name:ROCHE
    Full Title: FC + rituximab followed by rituximab maintenance treatment in patients with advanced untreated Indolent B-cell Non follicular Lymphomas: phase II study.
    Medical condition: Previously untreated CD20-positive B-cell advanced indolent non follicular non-Hodgkin Lymphoma (NHL).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004033-28 Sponsor Protocol Number: IPI-145-22 Start Date*: 2016-05-04
    Sponsor Name:Infinity Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination with Rituximab and Bendamustine vs Placebo Administered in Combination with Rituximab and Bendamustine in Subjects...
    Medical condition: Indolent Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) EE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-004158-17 Sponsor Protocol Number: GELTAMO-IMCL-2015 Start Date*: 2016-02-15
    Sponsor Name:GELTAMO (Grupo Cooperativo Español de Llinfoma/Trasplante Autólogo de Médula Ósea)
    Full Title: Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma.
    Medical condition: Mantle Cell Lyphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 01:08:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA